PURE Bioscience Appoints Peter C. Wulff as Chief Financial Officer

Published: Nov 09, 2012

SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has named Peter C. Wulff as Chief Financial Officer, effective November 5, 2012. Mr. Wulff has 25 years of financial and operating management experience, including more than 12 years as a senior-level executive in the life science industry. Most recently Mr. Wulff served as Chief Financial Officer, Vice President, Treasurer and Senior Vice President, Strategic Initiatives for Alphatec Holdings, Inc. (NASDAQ: ATEC) and its subsidiary, Alphatec Spine, Inc., a developer and manufacturer of spinal implant products. Michael L. Krall, President and CEO of PURE Bioscience, said, “Peter has a proven ability to manage rapid growth and oversee the development of successful new products and technologies. We are confident that his expertise will be of immediate benefit across our business, including optimizing our many current opportunities and creating new growth initiatives.”

Back to news